<DOC>
	<DOC>NCT00048139</DOC>
	<brief_summary>This study will assess the efficacy and safety of intermittent oral Xeloda administration in combination with irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>adult patients &gt;=18 years of age; locally advanced and/or metastatic colorectal cancer; &gt;=1 target lesion. previous treatment with Xeloda or irinotecan; previous systemic therapy for metastatic disease; progressive disease during previous adjuvant therapy or within 6 months of completion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>